Novel silver‐functionalized poly(ɛ‐caprolactone)/biphasic calcium phosphate scaffolds designed to counteract post‐surgical infections in orthopedic applications

In this study, we designed and developed novel poly(ε‐caprolactone) (PCL)‐based biomaterials, for use as bone scaffolds, through modification with both biphasic calcium phosphate (BCP), to impart bioactive/bioresorbable properties, and with silver nitrate, to provide antibacterial protection against Staphylococcus aureus, a microorganism involved in prosthetic joint infections (PJIs). Field emission scanning electron microscopy (FESEM) showed that the samples were characterized by square‐shaped macropores, and energy dispersive X‐ray spectroscopy analysis confirmed the presence of PCL and BCP phases, while inductively coupled plasma–mass spectrometry (ICP–MS) established the release of Ag+ in the medium (~0.15–0.8 wt% of initial Ag content). Adhesion assays revealed a significant (p < 0.0001) reduction in both adherent and planktonic staphylococci on the Ag‐functionalized biomaterials, and the presence of an inhibition halo confirmed Ag release from enriched samples. To assess the potential outcome in promoting bone integration, preliminary tests on sarcoma osteogenic‐2 (Saos‐2) cells indicated PCL and BCP/PCL biocompatibility, but a reduction in viability was observed for Ag‐added biomaterials. Due to their combined biodegrading and antimicrobial properties, the silver‐enriched BCP/PCL-based scaffolds showed good potential for engineering of bone tissue and for reducing PJIs as a microbial anti‐adhesive tool used in the delivery of targeted antimicrobial molecules, even if the amount of silver needs to be tuned to improve osteointegration.